<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName journalpublishing.dtd?>
<?SourceDTD.Version 2.3?>
<?ConverterInfo.XSLTName jp2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Front Oncol</journal-id>
    <journal-id journal-id-type="iso-abbrev">Front Oncol</journal-id>
    <journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id>
    <journal-title-group>
      <journal-title>Frontiers in Oncology</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2234-943X</issn>
    <publisher>
      <publisher-name>Frontiers Media S.A.</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">7381343</article-id>
    <article-id pub-id-type="doi">10.3389/fonc.2020.01097</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Oncology</subject>
        <subj-group>
          <subject>Original Research</subject>
        </subj-group>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>OSlgg: An Online Prognostic Biomarker Analysis Tool for Low-Grade Glioma</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>An</surname>
          <given-names>Yang</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <xref ref-type="author-notes" rid="fn002">
          <sup>†</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/743108/overview"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wang</surname>
          <given-names>Qiang</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <xref ref-type="author-notes" rid="fn002">
          <sup>†</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/647946/overview"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhang</surname>
          <given-names>Lu</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/702101/overview"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Sun</surname>
          <given-names>Fengjie</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/996299/overview"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhang</surname>
          <given-names>Guosen</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/695335/overview"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Dong</surname>
          <given-names>Huan</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/734374/overview"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Yingkun</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/995684/overview"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Peng</surname>
          <given-names>Yanyu</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/995690/overview"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Haojie</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/995653/overview"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhu</surname>
          <given-names>Wan</given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
          <sup>2</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/677026/overview"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Ji</surname>
          <given-names>Shaoping</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/651503/overview"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wang</surname>
          <given-names>Yunlong</given-names>
        </name>
        <xref ref-type="aff" rid="aff3">
          <sup>3</sup>
        </xref>
        <xref ref-type="corresp" rid="c001">
          <sup>*</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Guo</surname>
          <given-names>Xiangqian</given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
          <sup>1</sup>
        </xref>
        <xref ref-type="corresp" rid="c002">
          <sup>*</sup>
        </xref>
        <uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/605469/overview"/>
      </contrib>
    </contrib-group>
    <aff id="aff1"><sup>1</sup><institution>Department of Predictive Medicine, Institute of Biomedical Informatics, Cell Signal Transduction Laboratory, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, Kaifeng Key Laboratory of Cell Signal Transduction, School of Basic Medical Sciences, School of Software, Henan University</institution>, <addr-line>Kaifeng</addr-line>, <country>China</country></aff>
    <aff id="aff2"><sup>2</sup><institution>Department of Anesthesia, Stanford University</institution>, <addr-line>Stanford, CA</addr-line>, <country>United States</country></aff>
    <aff id="aff3"><sup>3</sup><institution>Henan Bioengineering Research Center</institution>, <addr-line>Zhengzhou</addr-line>, <country>China</country></aff>
    <author-notes>
      <fn fn-type="edited-by">
        <p>Edited by: Maciej Harat, Franciszek Lukaszczyk Oncology Centre, Poland</p>
      </fn>
      <fn fn-type="edited-by">
        <p>Reviewed by: Vidyasiri Vemulapalli, Dana–Farber Cancer Institute, United States; Maria Caffo, University of Messina, Italy</p>
      </fn>
      <corresp id="c001">*Correspondence: Yunlong Wang <email>biowyl@126.com</email></corresp>
      <corresp id="c002">Xiangqian Guo <email>xqguo@henu.edu.cn</email></corresp>
      <fn fn-type="other" id="fn001">
        <p>This article was submitted to Neuro-Oncology and Neurosurgical Oncology, a section of the journal Frontiers in Oncology</p>
      </fn>
      <fn fn-type="other" id="fn002">
        <p>†These authors have contributed equally to this work</p>
      </fn>
    </author-notes>
    <pub-date pub-type="epub">
      <day>07</day>
      <month>7</month>
      <year>2020</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2020</year>
    </pub-date>
    <volume>10</volume>
    <elocation-id>1097</elocation-id>
    <history>
      <date date-type="received">
        <day>10</day>
        <month>2</month>
        <year>2020</year>
      </date>
      <date date-type="accepted">
        <day>02</day>
        <month>6</month>
        <year>2020</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>Copyright © 2020 An, Wang, Zhang, Sun, Zhang, Dong, Li, Peng, Li, Zhu, Ji, Wang and Guo.</copyright-statement>
      <copyright-year>2020</copyright-year>
      <copyright-holder>An, Wang, Zhang, Sun, Zhang, Dong, Li, Peng, Li, Zhu, Ji, Wang and Guo</copyright-holder>
      <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
        <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
      </license>
    </permissions>
    <abstract>
      <p>Glioma is the most frequent primary brain tumor that causes high mortality and morbidity with poor prognosis. There are four grades of gliomas, I to IV, among which grade II and III are low-grade glioma (LGG). Although less aggressive, LGG almost universally progresses to high-grade glioma and eventual causes death if lacking of intervention. Current LGG treatment mainly depends on surgical resection followed by radiotherapy and chemotherapy, but the survival rates of LGG patients are low. Therefore, it is necessary to use prognostic biomarkers to classify patients into subgroups with different risks and guide clinical managements. Using gene expression profiling and long-term follow-up data, we established an <underline><bold>O</bold></underline>nline consensus <underline><bold>S</bold></underline>urvival analysis tool for LGG named OSlgg. OSlgg is comprised of 720 LGG cases from two independent cohorts. To evaluate the prognostic potency of genes, OSlgg employs the Kaplan-Meier plot with hazard ratio and p value to assess the prognostic significance of genes of interest. The reliability of OSlgg was verified by analyzing 86 previously published prognostic biomarkers of LGG. Using OSlgg, we discovered two novel potential prognostic biomarkers (<italic>CD302</italic> and <italic>FABP5</italic>) of LGG, and patients with the elevated expression of either <italic>CD302</italic> or <italic>FABP5</italic> present the unfavorable survival outcome. These two genes may be novel risk predictors for LGG patients after further validation. OSlgg is public and free to the users at <ext-link ext-link-type="uri" xlink:href="http://bioinfo.henu.edu.cn/LGG/LGGList.jsp">http://bioinfo.henu.edu.cn/LGG/LGGList.jsp</ext-link>.</p>
    </abstract>
    <kwd-group>
      <kwd>low-grade glioma</kwd>
      <kwd>prognostic biomarker</kwd>
      <kwd>gene expression profiling</kwd>
      <kwd>survival analysis</kwd>
      <kwd>survival outcome</kwd>
    </kwd-group>
    <counts>
      <fig-count count="9"/>
      <table-count count="5"/>
      <equation-count count="0"/>
      <ref-count count="60"/>
      <page-count count="15"/>
      <word-count count="6831"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="s1">
    <title>Introduction</title>
    <p>Glioma is the most frequent primary brain tumor with four grades from grade I to IV. Grade IV glioma is also known as glioblastoma, while grade II and III glioma refer to low-grade glioma (LGG) designated by World Health Organization (WHO) (<xref rid="B1" ref-type="bibr">1</xref>–<xref rid="B4" ref-type="bibr">4</xref>). LGG includes three histological types: astrocytoma, oligodendroglioma, and oligoastrocytoma (<xref rid="B4" ref-type="bibr">4</xref>–<xref rid="B6" ref-type="bibr">6</xref>), while oligoastrocytoma is no longer considered as a separate entity since the current WHO classification has included molecular markers (including IDH1 mutation and 1p/19q codeletion) to identify astrocytoma and oligodendroglioma, not oligoastrocytoma (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B7" ref-type="bibr">7</xref>). Although less aggressive than high-grade glioma, LGG eventually advances to high-grade glioma without intervention therapy (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B8" ref-type="bibr">8</xref>). For most LGG patients, the treatment is surgical excision followed by radiotherapy and/or chemotherapy including temozolamide (TMZ) and PCV (combination of procarbazine, lomustine, and vincristine) (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B9" ref-type="bibr">9</xref>). However, some patients would be tolerant or resistant to such uniform treatment and progress to relapse and eventual lead to death faster than the others (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B8" ref-type="bibr">8</xref>), maybe due to the molecular heterogeneity of LGG (<xref rid="B10" ref-type="bibr">10</xref>–<xref rid="B12" ref-type="bibr">12</xref>), so the optimum timing of the therapeutic schedule needs to be determined case by case (<xref rid="B13" ref-type="bibr">13</xref>).</p>
    <p>With the availability of public gene expression profiling data, more and more molecular predictive and prognostic indicators have recently been identified in LGG to guide the personalized therapy by informing which patients require early intervention and predicting the prognosis outcome (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B14" ref-type="bibr">14</xref>). However, it requires specific bioinformatics skills to perform prognosis analysis using these gene expression profiling data. It is desirable that users with limited bioinformatics skills can assess prognostic biomarkers for LGG using a convenient and easy-to-use bioinformatics tool. In the present study, we developed an easy-to-use web server named OSlgg, which provides a platform to evaluate the prognostic value of a gene of interest by applying Kaplan-Meier plot to present the association between candidate gene and survival rate, conduce to the clinical translation of potential prognostic biomarkers and targeted therapies for LGG patients.</p>
  </sec>
  <sec sec-type="methods" id="s2">
    <title>Methods</title>
    <sec>
      <title>Data Collection</title>
      <p>Gene expression profiling and related long-term follow-up data of low-grade gliomas were collected from GEO (Gene Expression Omnibus) and TCGA (The Cancer Genome Atlas) database. For dataset searching, the keywords, including “low-grade glioma,” “gene expression,” and “survival” were used in GEO database. The criteria for dataset accession are as followed: (1) has gene expression profiling data; (2) includes the long-term follow-up data of patients; (3) contains more than 50 LGG cases to enable valid survival analysis. Thus, one GEO dataset (GSE107850) with 195 LGG cases was collected (<xref rid="T1" ref-type="table">Table 1</xref>). For TCGA dataset, gene expression profiling (RNA-seq, level-3, HiSeqV2) and follow-up data of 525 LGG cases were downloaded in 2019 (<xref rid="T1" ref-type="table">Table 1</xref>). The survival terms of follow-up data include OS (overall survival), RFS (relapse-free survival) and PFS (progression-free survival) (<xref rid="T1" ref-type="table">Table 1</xref>). And the clinicopathologic characteristics of LGG patients are summarized in <xref ref-type="supplementary-material" rid="SM8">Table S1</xref>.</p>
      <table-wrap id="T1" position="float">
        <label>Table 1</label>
        <caption>
          <p>Summary of datasets in OSlgg.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Dataset</bold>
              </th>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Sample size</bold>
              </th>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Data type</bold>
              </th>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Platform</bold>
              </th>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Survival terms</bold>
              </th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">TCGA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">525</td>
              <td valign="top" align="left" rowspan="1" colspan="1">RNA-seq</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Illumina HiSeqV2</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS, RFS</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">GSE107850</td>
              <td valign="top" align="left" rowspan="1" colspan="1">195</td>
              <td valign="top" align="left" rowspan="1" colspan="1">cDNA array</td>
              <td valign="top" align="left" rowspan="1" colspan="1">GPL14951</td>
              <td valign="top" align="left" rowspan="1" colspan="1">PFS</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Total</td>
              <td valign="top" align="left" rowspan="1" colspan="1">720</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
    <sec>
      <title>Development of OSlgg</title>
      <p>OSlgg adopts object-orient programming method to develop each function module based on the structure of B/S (Browser/Server). Java and R are used to achieve server-side. The web server function was divided into three parts, including UI (user interface), data analysis and data access. Java and R language are used for data analysis and data access, respectively. UI is developed by HTML5, JQurey, and JSP. And the real time communication between web server and clients is achieved by Servlet. Gene expression profiling and clinical data were stored in relational tables in SQL Server database. System architecture flow diagram is presented in <xref ref-type="fig" rid="F1">Figure 1</xref>, as previously described (<xref rid="B15" ref-type="bibr">15</xref>–<xref rid="B18" ref-type="bibr">18</xref>). OSlgg can be accessed at <ext-link ext-link-type="uri" xlink:href="https://www.bioinfo.henu.edu.cn/LGG/LGGList.jsp">bioinfo.henu.edu.cn/LGG/LGGList.jsp</ext-link>.</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Flowchart of web server OSlgg architecture.</p>
        </caption>
        <graphic xlink:href="fonc-10-01097-g0001"/>
      </fig>
    </sec>
    <sec>
      <title>Verification of Prognostic Biomarkers in OSlgg</title>
      <p>To assess the reliability of prognostic analysis of OSlgg web server, previously published prognostic biomarkers of LGG were searched in PubMed using the keywords “low-grade glioma,” “survival,” “prognosis” and “biomarker.” As a result, we collected 93 papers with 86 reported prognostic biomarkers. The prognostic abilities of these prognostic genes were assessed in OSlgg.</p>
    </sec>
    <sec>
      <title>Discovery of Novel Prognostic Biomarkers in OSlgg</title>
      <p>To identify novel prognostic biomarker for LGG, we genome-widely analyzed the prognostic values of human genes using Cox regression analysis. Genes significantly related to prognosis were selected (cox <italic>p</italic> value &lt; 0.05), including <italic>CD302</italic> and <italic>FABP5</italic>. As they exhibited significant correlation with prognosis (<italic>p</italic> value &lt; 0.000001) in Cox regression analysis, we further evaluated the prognostic values of <italic>CD302</italic> or <italic>FABP5</italic> in OSlgg. In addition, correlation analysis and GSEA (Gene Set Enrichment Analysis) were performed to investigate the functions of <italic>CD302</italic> and <italic>FABP5</italic>. Correlations between the expression levels of <italic>CD302</italic> or <italic>FABP5</italic> and 86 previously reported LGG prognostic biomarkers were assessed using Spearman's rank correlation test of a non-normal distribution as continuous measures and TCGA data. For GSEA analysis, patients from TCGA cohort were split into two subgroups according to <italic>CD302</italic> or <italic>FABP5</italic> expression, named as CD302 or FABP5 Upper 25% expression and Lower 75% expression. Then GSEA was run to investigate the gene sets enriched in each subgroup.</p>
    </sec>
    <sec>
      <title>Statistical Analysis</title>
      <p>Statistical evaluation was performed with SPSS 19.0 (SPSS Inc., Chicago, IL, USA) and GraphPad Prism 7.0 (GraphPad Inc., La Jolla, CA, USA). The association between <italic>CD302/FABP5</italic> expression and clinicopathological characteristics was measured by using Chi-square test. Students' t-test and one-way ANOVA (analysis of variance) were employed to determine the significance of expression difference of <italic>CD302/FABP5</italic> expression in distinct histologic grades and primary therapy outcomes, respectively. Univariate and multivariate cox regression analysis of <italic>CD302/FABP5</italic> expression and clinical factors associated with survival of LGG patients were conducted by using SPSS. A value of <italic>p</italic> &lt; 0.05 was considered to be statistical significant.</p>
    </sec>
  </sec>
  <sec sec-type="results" id="s3">
    <title>Results</title>
    <sec>
      <title>Clinical Features of LGG Patients in OSlgg</title>
      <p>In TCGA cohort, the median age of 525 LGG patients is 41. Three histological types were included. Specifically, astrocytoma accounts for 37% of all the LGG patients (<italic>n</italic> = 196), oligoastrocytoma accounts for 26% (<italic>n</italic> = 134) and oligodendroglioma accounts for 37% (<italic>n</italic> = 195) (<xref ref-type="supplementary-material" rid="SM8">Table S1</xref>). A summary of clinical features for each cohort was shown in <xref ref-type="supplementary-material" rid="SM8">Table S1</xref>. The Kaplan-Meier plots for LGG patients in OSlgg grouped by different histological type, histologic grade, IDH status, primary and follow-up therapy outcome were presented in <xref ref-type="fig" rid="F2">Figure 2</xref>. As shown, these clinical features were significantly associated with survival (OS or PFS), respectively (<xref ref-type="fig" rid="F2">Figure 2</xref>).</p>
      <fig id="F2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Survival analysis of LGG patients with different clinical features in OSlgg. Kaplan-Meier plots for <bold>(A)</bold> Primary therapy outcome, <bold>(B)</bold> Histological type, <bold>(C)</bold> Neoplasm histologic grade, <bold>(D)</bold> Follow-up therapy outcome, <bold>(E)</bold> IDH status in terms of OS in TCGA cohort; <bold>(F)</bold> IDH status in terms of PFS in GSE107850 cohort.</p>
        </caption>
        <graphic xlink:href="fonc-10-01097-g0002"/>
      </fig>
    </sec>
    <sec>
      <title>Application of OSlgg</title>
      <p>In OSlgg, “Gene symbol,” “Data Source,” “Survival,” and “Split patients by” are set as the four main parameters to assess the prognostic value of a gene of interest (<xref ref-type="fig" rid="F3">Figures 3</xref>, <xref ref-type="fig" rid="F4">4</xref>). Typically, the official gene symbol is required to be filled into the “Gene symbol” input box by users. Drop-down menu of “Data source” offers two options for users to pick either of the two independent cohorts (TCGA and GSE107850) (<xref ref-type="fig" rid="F3">Figure 3B</xref>). Next, users may select the cut-off, by which patients can be split into 2-4 groups according to the expression of the inquired gene (<xref ref-type="fig" rid="F3">Figure 3C</xref>). Furthermore, according to user's special needs, users may divide LGG patients into subgroups by setting different clinical factors, such as histological type, IDH status, therapy outcome, gender, treatment, etc. (<xref ref-type="fig" rid="F3">Figures 3</xref>, <xref ref-type="fig" rid="F4">4</xref>). Then user could click the “Kaplan-Meier plot” button, OSlgg will receive the query and output the analysis results to users in a graphical manner on the web page, present the Kaplan-Meier survival curve, HR (with 95% confidence interval) and <italic>p</italic> value.</p>
      <fig id="F3" position="float">
        <label>Figure 3</label>
        <caption>
          <p>Overview of OSlgg subfield interface for TCGA cohort. <bold>(A)</bold> Screenshot of OSlgg main interface. <bold>(B–F)</bold> Input interfaces of OSlgg for Data source <bold>(B)</bold>, cut-off <bold>(C)</bold>, Histological type <bold>(D)</bold>, IDH1 mutation <bold>(E)</bold>, and therapy outcome <bold>(F)</bold>.</p>
        </caption>
        <graphic xlink:href="fonc-10-01097-g0003"/>
      </fig>
      <fig id="F4" position="float">
        <label>Figure 4</label>
        <caption>
          <p>Overview of OSlgg subfield interface for GSE107850 cohort. <bold>(A)</bold> Screenshot of OSlgg main interface. <bold>(B–E)</bold> Input interfaces of OSlgg for Gender <bold>(B)</bold>, Treatment <bold>(C)</bold>, Histology <bold>(D)</bold>, and IDH status <bold>(E)</bold>.</p>
        </caption>
        <graphic xlink:href="fonc-10-01097-g0004"/>
      </fig>
    </sec>
    <sec>
      <title>Verification of Previously Published LGG Prognostic Biomarkers in OSlgg</title>
      <p>To test the reliability of OSlgg web server in prognosis analysis, we collected 86 previously published prognostic biomarkers from 93 papers, including β-catenin, NF-kB, vimentin, Cyclin A, CD31, etc., and assessed their prognostic performances in OSlgg. The analysis results by OSlgg showed that all the 86 biomarkers have predictive values in OSlgg, which was consistent with previous reports (<xref rid="T2" ref-type="table">Table 2</xref> and <xref ref-type="supplementary-material" rid="SM9">Table S2</xref>, <xref ref-type="fig" rid="F5">Figure 5</xref> and <xref ref-type="supplementary-material" rid="SM1">Figure S1</xref>), and the housekeeping genes were also presented as negative controls (<xref ref-type="supplementary-material" rid="SM2">Figure S2</xref>). Among these, N-cadherin (encoded by <italic>CDH2</italic> gene), EGFR, IDH1, VEGF, nestin (encoded by <italic>NES</italic> gene), survivin (encoded by <italic>BIRC5</italic> gene), PCNA, Ki-67 (encoded by <italic>MKI67</italic> gene), and p27 (encoded by <italic>CDKN1B</italic> gene) were frequently reported as risk predictors for LGG (<xref rid="B19" ref-type="bibr">19</xref>–<xref rid="B34" ref-type="bibr">34</xref>). As previously described, these genes were significantly associated with survival (OS, RFS and PFS) in OSlgg (<xref rid="T2" ref-type="table">Table 2</xref>, <xref ref-type="fig" rid="F5">Figure 5</xref> and <xref ref-type="supplementary-material" rid="SM1">Figure S1</xref>). The elevated expression of <italic>CDH2, EGFR, IDH1, VEGFA, NES, BIRC5, PCNA</italic>, and <italic>MKI67</italic> indicated the unfavorable outcome, while the increased <italic>CDKN1B</italic> expression predicted a favorable outcome for LGG patients (<xref rid="T2" ref-type="table">Table 2</xref>, <xref ref-type="fig" rid="F5">Figure 5</xref> and <xref ref-type="supplementary-material" rid="SM1">Figure S1</xref>). In the remaining 77 biomarkers, 59 genes were adverse predictors, and 18 genes were beneficial predictors (<xref ref-type="supplementary-material" rid="SM9">Table S2</xref>).</p>
      <table-wrap id="T2" position="float">
        <label>Table 2</label>
        <caption>
          <p>Verification of previously reported LGG prognostic predictors in OSlgg.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Gene symbol</bold>
              </th>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Biomarker name</bold>
              </th>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Clinical survival terms</bold>
              </th>
              <th valign="top" align="center" colspan="5" style="border-bottom: thin solid #000000;" rowspan="1">
                <bold>In OSlgg</bold>
              </th>
              <th valign="top" align="center" colspan="5" style="border-bottom: thin solid #000000;" rowspan="1">
                <bold>In reference</bold>
              </th>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Worse prognosis (expression)</bold>
              </th>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>References</bold>
              </th>
            </tr>
            <tr>
              <th rowspan="1" colspan="1"/>
              <th rowspan="1" colspan="1"/>
              <th rowspan="1" colspan="1"/>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Cut-off</bold>
              </th>
              <th valign="top" align="center" rowspan="1" colspan="1">
                <bold><italic>p</italic> value</bold>
              </th>
              <th valign="top" align="center" rowspan="1" colspan="1">
                <bold>HR</bold>
              </th>
              <th valign="top" align="center" rowspan="1" colspan="1">
                <bold>95%CI</bold>
              </th>
              <th valign="top" align="center" rowspan="1" colspan="1">
                <bold>Case</bold>
              </th>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Cut-off</bold>
              </th>
              <th valign="top" align="center" rowspan="1" colspan="1">
                <bold><italic>p</italic> value</bold>
              </th>
              <th valign="top" align="center" rowspan="1" colspan="1">
                <bold>Case</bold>
              </th>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Detection level</bold>
              </th>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Validation</bold>
              </th>
              <th rowspan="1" colspan="1"/>
              <th rowspan="1" colspan="1"/>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">CDH2</td>
              <td valign="top" align="left" rowspan="1" colspan="1">N-cadherin</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25%</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td>
              <td valign="top" align="center" rowspan="1" colspan="1">2.3827</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.6847-3.3699</td>
              <td valign="top" align="center" rowspan="1" colspan="1">525</td>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">OS: <italic>p</italic> &lt; 0.001</td>
              <td valign="top" align="center" rowspan="1" colspan="1">343</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Yes, IHC assay</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Higher</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B19" ref-type="bibr">19</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">RFS</td>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0026</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.7159</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.2069-2.4396</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">EGFR</td>
              <td valign="top" align="left" rowspan="1" colspan="1">EGFR</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25%</td>
              <td valign="top" align="center" rowspan="1" colspan="1">2e-04</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.9435</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.3703-2.7565</td>
              <td valign="top" align="center" rowspan="1" colspan="1">525</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper <italic>n</italic> = 7 /Lower <italic>n</italic> = 18</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS: <italic>p</italic> &lt; 0.01</td>
              <td valign="top" align="center" rowspan="1" colspan="1">25</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Yes, IHC assay</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Higher</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B21" ref-type="bibr">21</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">RFS</td>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0434</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.4379</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.0108-2.0453</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">IDH1</td>
              <td valign="top" align="left" rowspan="1" colspan="1">IDH1</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 50%</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0024</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.7174</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.2118-2.4338</td>
              <td valign="top" align="center" rowspan="1" colspan="1">525</td>
              <td valign="top" align="left" rowspan="1" colspan="1">WT <italic>n</italic> = 108 /MT <italic>n</italic> = 310</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS: <italic>p</italic> = 0.015</td>
              <td valign="top" align="center" rowspan="1" colspan="1">418</td>
              <td valign="top" align="left" rowspan="1" colspan="1">DNA pyrosequencing</td>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">Higher</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B22" ref-type="bibr">22</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">RFS</td>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0501</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.3913</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.9999-1.9359</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">VEGFA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">VEGFA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25%</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td>
              <td valign="top" align="center" rowspan="1" colspan="1">2.5754</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.8074-3.6696</td>
              <td valign="top" align="center" rowspan="1" colspan="1">525</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper <italic>n</italic> = 39 /Lower <italic>n</italic> = 35</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS: <italic>p</italic> = 0.002</td>
              <td valign="top" align="center" rowspan="1" colspan="1">74</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Yes, IHC assay</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Higher</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B24" ref-type="bibr">24</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">RFS</td>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td>
              <td valign="top" align="center" rowspan="1" colspan="1">2.1336</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.4857-3.0641</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">PFS</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25%</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0296</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.604</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.0478-2.4555</td>
              <td valign="top" align="center" rowspan="1" colspan="1">195</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">NES</td>
              <td valign="top" align="left" rowspan="1" colspan="1">nestin</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25%</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0178</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.5426</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.0779-2.2076</td>
              <td valign="top" align="center" rowspan="1" colspan="1">525</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper <italic>n</italic> = 25 /Lower <italic>n</italic> = 25</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS: <italic>p</italic> = 0.0004</td>
              <td valign="top" align="center" rowspan="1" colspan="1">50</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Yes, IHC assay</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Higher</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B25" ref-type="bibr">25</xref>–<xref rid="B27" ref-type="bibr">27</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">RFS</td>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">0.02</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.5177</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.0679-2.1569</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">BIRC5</td>
              <td valign="top" align="left" rowspan="1" colspan="1">survivin</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 30%</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td>
              <td valign="top" align="center" rowspan="1" colspan="1">2.5472</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.8055-3.5937</td>
              <td valign="top" align="center" rowspan="1" colspan="1">525</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper <italic>n</italic> = 13 /Lower <italic>n</italic> = 8</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS: <italic>p</italic> = 0.007</td>
              <td valign="top" align="center" rowspan="1" colspan="1">21</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Yes, IHC assay</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Higher</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B28" ref-type="bibr">28</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">RFS</td>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.9996</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.437-2.7824</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">PFS</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25%</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0156</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.6915</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.1047-2.5899</td>
              <td valign="top" align="center" rowspan="1" colspan="1">195</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">PCNA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">PCNA</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 25%</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td>
              <td valign="top" align="center" rowspan="1" colspan="1">2.7723</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.9575-3.9263</td>
              <td valign="top" align="center" rowspan="1" colspan="1">525</td>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">OS: <italic>p</italic> = 0.0009</td>
              <td valign="top" align="center" rowspan="1" colspan="1">85</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Yes, IHC assay</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Higher</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B29" ref-type="bibr">29</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">RFS</td>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">6e-04</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.8521</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.3048-2.629</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">MKI67</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Ki-67</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper 30%</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td>
              <td valign="top" align="center" rowspan="1" colspan="1">2.4146</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.7159-3.3978</td>
              <td valign="top" align="center" rowspan="1" colspan="1">525</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper <italic>n</italic> = 128 /Lower <italic>n</italic> = 52</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS: <italic>p</italic> = 0.047</td>
              <td valign="top" align="center" rowspan="1" colspan="1">180</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Yes, IHC assay</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Higher</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B30" ref-type="bibr">30</xref>–<xref rid="B32" ref-type="bibr">32</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">RFS</td>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td>
              <td valign="top" align="center" rowspan="1" colspan="1">2.1909</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.5759-3.0458</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">CDKN1B</td>
              <td valign="top" align="left" rowspan="1" colspan="1">p27</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Lower 50%</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0073</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.6099</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.137-2.2793</td>
              <td valign="top" align="center" rowspan="1" colspan="1">525</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Upper <italic>n</italic> = 30 /Lower <italic>n</italic> = 28</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS: <italic>p</italic> = 0.007</td>
              <td valign="top" align="center" rowspan="1" colspan="1">77</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Protein</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Yes, IHC assay</td>
              <td valign="top" align="left" rowspan="1" colspan="1">Lower</td>
              <td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B34" ref-type="bibr">34</xref>)</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">RFS</td>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">0.0266</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.455</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.0444-2.027</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <p><italic>WT, wild type; MT, mutation</italic>.</p>
        </table-wrap-foot>
      </table-wrap>
      <fig id="F5" position="float">
        <label>Figure 5</label>
        <caption>
          <p>Verification of previously reported prognostic biomarkers in OSlgg. Kaplan[[Inline Image]]-Meier plots for <bold>(A)</bold>
<italic>CDH2</italic>, <bold>(B)</bold>
<italic>EGFR</italic>, <bold>(C)</bold>
<italic>IDH1</italic>, <bold>(D)</bold>
<italic>VEGFA</italic>, <bold>(E)</bold>
<italic>NES</italic>, <bold>(F)</bold>
<italic>BIRC5</italic>, <bold>(G)</bold>
<italic>PCNA</italic>, <bold>(H)</bold>
<italic>MKI67</italic>, and <bold>(I)</bold>
<italic>CDKN1B</italic> in terms of OS. <italic>p</italic>-value, confidence interval (95%CI) and number at risk are as shown. The y-axis represents survival rate and the x-axis represents survival time (months).</p>
        </caption>
        <graphic xlink:href="fonc-10-01097-g0005"/>
      </fig>
    </sec>
    <sec>
      <title>Discovery of Novel Potential Prognostic Biomarkers in OSlgg</title>
      <p>In order to discover novel risk predictors for LGG, we analyzed the prognostic abilities of all known human genes using Cox regression. As a result, two genes were identified as potential biomarkers, including <italic>CD302</italic> and <italic>FABP5</italic>, which were both significantly associated with survival (OS, RFS and PFS) in OSlgg (<xref ref-type="fig" rid="F6">Figure 6</xref> and <xref rid="T3" ref-type="table">Table 3</xref>). Moreover, we found that patients with elevated <italic>CD302</italic> or <italic>FABP5</italic> expression exhibited worse survival in both TCGA (OS and RFS) and GSE107850 (PFS) datasets, while the lower expression patients presented better survival (<xref ref-type="fig" rid="F6">Figure 6</xref> and <xref rid="T3" ref-type="table">Table 3</xref>), indicating that both <italic>CD302</italic> and <italic>FABP5</italic> could predict the adverse outcome as unfavorable predictors.</p>
      <fig id="F6" position="float">
        <label>Figure 6</label>
        <caption>
          <p>Identification of potential prognostic biomarkers in OSlgg. Kaplan-Meier plots for low (green) and high (red) <italic>CD302</italic>
<bold>(A–C)</bold> or <italic>FABP5</italic>-expression <bold>(D–F)</bold> in TCGA cohort <bold>(A,B,D,E)</bold> and GSE107850 cohort <bold>(C,F)</bold>. <bold>(A,D)</bold> OS, Overall survival; <bold>(B,E)</bold> RFS, Relapse-free survival; <bold>(C,F)</bold> PFS, Progression-free survival. <italic>p</italic>-value, confidence interval (95%CI) and number at risk are as shown. The y-axis represents survival rate and the x-axis represents survival time (months).</p>
        </caption>
        <graphic xlink:href="fonc-10-01097-g0006"/>
      </fig>
      <table-wrap id="T3" position="float">
        <label>Table 3</label>
        <caption>
          <p>Identification of potential LGG prognostic biomarkers in OSlgg.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Gene symbol</bold>
              </th>
              <th valign="top" align="center" colspan="5" style="border-bottom: thin solid #000000;" rowspan="1">
                <bold>In OSlgg</bold>
              </th>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Case number</bold>
              </th>
            </tr>
            <tr>
              <th rowspan="1" colspan="1"/>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Cut-off</bold>
              </th>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Survival terms</bold>
              </th>
              <th valign="top" align="center" rowspan="1" colspan="1">
                <bold><italic>p</italic> value</bold>
              </th>
              <th valign="top" align="center" rowspan="1" colspan="1">
                <bold>HR</bold>
              </th>
              <th valign="top" align="center" rowspan="1" colspan="1">
                <bold>95%CI</bold>
              </th>
              <th rowspan="1" colspan="1"/>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">CD302</td>
              <td valign="top" align="left" rowspan="1" colspan="1">upper 25%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td>
              <td valign="top" align="center" rowspan="1" colspan="1">2.9064</td>
              <td valign="top" align="center" rowspan="1" colspan="1">2.0427-4.1353</td>
              <td valign="top" align="center" rowspan="1" colspan="1">525</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">RFS</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td>
              <td valign="top" align="center" rowspan="1" colspan="1">2.2226</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.5636-3.1594</td>
              <td valign="top" align="center" rowspan="1" colspan="1">525</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">PFS</td>
              <td valign="top" align="center" rowspan="1" colspan="1">3e-04</td>
              <td valign="top" align="center" rowspan="1" colspan="1">2.1203</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.4057-3.1982</td>
              <td valign="top" align="center" rowspan="1" colspan="1">195</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">FABP5</td>
              <td valign="top" align="left" rowspan="1" colspan="1">upper 25%</td>
              <td valign="top" align="left" rowspan="1" colspan="1">OS</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.0001</td>
              <td valign="top" align="center" rowspan="1" colspan="1">2.9936</td>
              <td valign="top" align="center" rowspan="1" colspan="1">2.1227-4.222</td>
              <td valign="top" align="center" rowspan="1" colspan="1">525</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">RFS</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1e-04</td>
              <td valign="top" align="center" rowspan="1" colspan="1">2.0296</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.4174-2.9063</td>
              <td valign="top" align="center" rowspan="1" colspan="1">525</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="left" rowspan="1" colspan="1">PFS</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1e-04</td>
              <td valign="top" align="center" rowspan="1" colspan="1">2.2445</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.4805-3.4027</td>
              <td valign="top" align="center" rowspan="1" colspan="1">195</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>To determine whether the prognostic significances of <italic>CD302</italic> and <italic>FABP5</italic> are caused by correlation with the previously reported prognostic genes, the correlation analysis between <italic>CD302/FABP5</italic> and the 86 reported prognostic biomarkers were performed, and showed that <italic>CD302/FABP5</italic> were positively correlated with 6 reported prognostic genes, including <italic>RAB34, CHI3L1, VIM, YAP1, FTL</italic>, and <italic>MMP14</italic> (<xref ref-type="fig" rid="F7">Figure 7A</xref>). Among these, <italic>RAB34</italic> is positively associated with both <italic>CD302</italic> and <italic>FABP5, CHI3L1</italic> is positively associated with <italic>FABP5</italic>, and the remaining four genes are all positively correlated with <italic>CD302</italic> (<xref ref-type="fig" rid="F7">Figure 7A</xref>). The GSEA analysis of LGG cases showed that those cases with high <italic>CD302</italic> expression enriched gene sets involved in JAK/STAT signaling pathway, cytokine receptor interaction, and primary immunodeficiency (<xref ref-type="fig" rid="F7">Figure 7B</xref>). And the same analysis found that LGG cases with higher <italic>FABP5</italic> expression enriched gene sets including ECM receptor interaction, cytokine receptor interaction and JAK/STAT signaling pathway (<xref ref-type="fig" rid="F7">Figure 7C</xref>). Moreover, LGG with <italic>CD302</italic> overexpression presented <italic>GPR65</italic> and <italic>PIK3CG</italic> up-regulation, while <italic>CHI3L1</italic> and <italic>RAB36</italic> were up-regulated in tumors with <italic>FABP5</italic> overexpression (<xref ref-type="fig" rid="F7">Figures 7D,E</xref>). In addition, we found that <italic>GPR65, PIK3CG</italic>, and <italic>RAB36</italic> have prognostic abilities in LGG, the elevated expression of which were significantly associated with worse survival of LGG patients (<xref ref-type="supplementary-material" rid="SM9">Table S2</xref> and <xref ref-type="supplementary-material" rid="SM3">Figure S3</xref>). As <xref ref-type="supplementary-material" rid="SM4">Figure S4</xref> showed, there is no significant difference of the copy numbers between <italic>CD302</italic> or <italic>FABP5</italic> higher and lower expression groups, respectively, indicating the prognostic significance of <italic>CD302</italic> and <italic>FABP5</italic> is not caused by genomic copy number changes.</p>
      <fig id="F7" position="float">
        <label>Figure 7</label>
        <caption>
          <p>Correlation and GSEA analysis of <italic>CD302</italic> and <italic>FABP5</italic>. <bold>(A)</bold> Correlation analysis between <italic>CD302</italic> or <italic>FABP5</italic> and the previously reported prognostic biomarkers by Spearman's rank correlation test with correlation coefficient marked on the matrix plot. <bold>(B–E)</bold> GSEA analysis of tumors with high versus low expression of <italic>CD302</italic> and <italic>FABP5</italic>. LGG patients were split into two subgroups according to <italic>CD302</italic> or <italic>FABP5</italic> expression, named as CD302 or FABP5 Upper 25% expression and Lower 75% expression. <bold>(B,C)</bold> Gene sets enriched in <italic>CD302</italic> and <italic>FABP5</italic> overexpressing LGG cases, respectively. <bold>(D,E)</bold> GSEA heat maps for differential expression genes enriched in <italic>CD302</italic> and <italic>FABP5</italic> overexpressing LGG cases, respectively.</p>
        </caption>
        <graphic xlink:href="fonc-10-01097-g0007"/>
      </fig>
    </sec>
    <sec>
      <title>Independent Prognostic and Clinical Significance of CD302 and FABP5</title>
      <p>To further investigate the relationship between <italic>CD302</italic>/<italic>FABP5</italic> and clinical factors, we analyzed the expression differences of <italic>CD302</italic>/<italic>FABP5</italic> between LGG subgroups with distinct clinical features, the results showed that LGG patients suffered from histologic grade 3 and progressive disease had significant higher expression of <italic>CD302</italic>/<italic>FABP5</italic>, respectively (<xref ref-type="supplementary-material" rid="SM5">Figure S5</xref>). In addition, as shown in <xref rid="T4" ref-type="table">Table 4</xref>, the expression of <italic>CD302</italic>/<italic>FABP5</italic> was significantly associated with histologic grade and primary therapy outcome. The higher <italic>CD302</italic> and <italic>FABP5</italic> expression subgroup presented a significantly higher ratio of patients in histologic grade 3 (91/40 vs. 178/215, <italic>p</italic> &lt; 0.001 and 85/46 vs. 184/209, <italic>p</italic> &lt; 0.001) compared to the lower <italic>CD302</italic> and <italic>FABP5</italic> subgroup, respectively (<xref rid="T4" ref-type="table">Table 4</xref>). The following multivariate analysis confirmed that the elevated <italic>CD302</italic>/<italic>FABP5</italic> expression is an independent prognostic indicator of LGG survival (HR: 1.842, 95% CI: 1.232-2.754, <italic>p</italic> = 0.003, and HR: 2.187, 95% CI: 1.488-3.214, <italic>p</italic> &lt; 0.001), respectively (<xref rid="T5" ref-type="table">Table 5</xref>).</p>
      <table-wrap id="T4" position="float">
        <label>Table 4</label>
        <caption>
          <p>The association of CD302 or FABP5 expression with clinical features in LGG patients.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Variables</bold>
              </th>
              <th valign="top" align="center" rowspan="1" colspan="1">
                <bold>No. of patient</bold>
              </th>
              <th valign="top" align="center" colspan="2" style="border-bottom: thin solid #000000;" rowspan="1">
                <bold>CD302 expression</bold>
              </th>
              <th valign="top" align="center" rowspan="1" colspan="1">
                <bold>χ2</bold>
              </th>
              <th valign="top" align="center" rowspan="1" colspan="1">
                <bold><italic>p</italic> value</bold>
              </th>
              <th valign="top" align="center" colspan="2" style="border-bottom: thin solid #000000;" rowspan="1">
                <bold>FABP5 expression</bold>
              </th>
              <th valign="top" align="center" rowspan="1" colspan="1">
                <bold>χ2</bold>
              </th>
              <th valign="top" align="center" rowspan="1" colspan="1">
                <bold><italic>p</italic> value</bold>
              </th>
            </tr>
            <tr>
              <th rowspan="1" colspan="1"/>
              <th rowspan="1" colspan="1"/>
              <th valign="top" align="center" rowspan="1" colspan="1">
                <bold>Upper</bold>
                <break/>
                <bold>25%</bold>
              </th>
              <th valign="top" align="center" rowspan="1" colspan="1">
                <bold>Lower</bold>
                <break/>
                <bold>75%</bold>
              </th>
              <th rowspan="1" colspan="1"/>
              <th rowspan="1" colspan="1"/>
              <th valign="top" align="center" rowspan="1" colspan="1">
                <bold>Upper</bold>
                <break/>
                <bold>25%</bold>
              </th>
              <th valign="top" align="center" rowspan="1" colspan="1">
                <bold>Lower</bold>
                <break/>
                <bold>75%</bold>
              </th>
              <th rowspan="1" colspan="1"/>
              <th rowspan="1" colspan="1"/>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Histologic grade</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">22.981</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt; 0.001</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">12.836</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt; 0.001</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1"> G2</td>
              <td valign="top" align="center" rowspan="1" colspan="1">255</td>
              <td valign="top" align="center" rowspan="1" colspan="1">40</td>
              <td valign="top" align="center" rowspan="1" colspan="1">215</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">46</td>
              <td valign="top" align="center" rowspan="1" colspan="1">209</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1"> G3</td>
              <td valign="top" align="center" rowspan="1" colspan="1">269</td>
              <td valign="top" align="center" rowspan="1" colspan="1">91</td>
              <td valign="top" align="center" rowspan="1" colspan="1">178</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">85</td>
              <td valign="top" align="center" rowspan="1" colspan="1">184</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Unknown</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Therapy outcome</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">29.313</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt; 0.001</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">28.983</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt; 0.001</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Complete response</td>
              <td valign="top" align="center" rowspan="1" colspan="1">133</td>
              <td valign="top" align="center" rowspan="1" colspan="1">17</td>
              <td valign="top" align="center" rowspan="1" colspan="1">116</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">17</td>
              <td valign="top" align="center" rowspan="1" colspan="1">116</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Partial response</td>
              <td valign="top" align="center" rowspan="1" colspan="1">65</td>
              <td valign="top" align="center" rowspan="1" colspan="1">11</td>
              <td valign="top" align="center" rowspan="1" colspan="1">54</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">10</td>
              <td valign="top" align="center" rowspan="1" colspan="1">55</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Progressive disease</td>
              <td valign="top" align="center" rowspan="1" colspan="1">114</td>
              <td valign="top" align="center" rowspan="1" colspan="1">47</td>
              <td valign="top" align="center" rowspan="1" colspan="1">67</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">46</td>
              <td valign="top" align="center" rowspan="1" colspan="1">68</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Stable disease</td>
              <td valign="top" align="center" rowspan="1" colspan="1">137</td>
              <td valign="top" align="center" rowspan="1" colspan="1">34</td>
              <td valign="top" align="center" rowspan="1" colspan="1">103</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td valign="top" align="center" rowspan="1" colspan="1">32</td>
              <td valign="top" align="center" rowspan="1" colspan="1">105</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Unknown</td>
              <td valign="top" align="center" rowspan="1" colspan="1">76</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <table-wrap id="T5" position="float">
        <label>Table 5</label>
        <caption>
          <p>Univariate and multivariate analysis of factors associated with LGG survival.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th valign="top" align="left" rowspan="1" colspan="1">
                <bold>Subgroup</bold>
              </th>
              <th valign="top" align="center" colspan="2" style="border-bottom: thin solid #000000;" rowspan="1">
                <bold>Univariate Analysis</bold>
              </th>
              <th valign="top" align="center" colspan="2" style="border-bottom: thin solid #000000;" rowspan="1">
                <bold>Multivariate Analysis</bold>
              </th>
            </tr>
            <tr>
              <th rowspan="1" colspan="1"/>
              <th valign="top" align="center" rowspan="1" colspan="1">
                <bold>Hazard ratio (95% CI)</bold>
              </th>
              <th valign="top" align="center" rowspan="1" colspan="1">
                <bold><italic>p</italic> value</bold>
              </th>
              <th valign="top" align="center" rowspan="1" colspan="1">
                <bold>Hazard ratio (95% CI)</bold>
              </th>
              <th valign="top" align="center" rowspan="1" colspan="1">
                <bold><italic>p</italic> value</bold>
              </th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">All patients (<italic>N</italic> = 525)</td>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
              <td rowspan="1" colspan="1"/>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Histologic type</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.757 (0.621–0.922)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.006</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.903 (0.725–1.125)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.363</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Histologic grade (<italic>N</italic> = 524)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">3.354 (2.298–4.895)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td>
              <td valign="top" align="center" rowspan="1" colspan="1">2.387 (1.577–3.612)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">Primary therapy outcome (<italic>N</italic> = 449)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.527 (1.267–1.839)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.461 (1.201–1.777)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">CD302 expression</td>
              <td valign="top" align="center" rowspan="1" colspan="1">2.899 (2.038–4.124)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td>
              <td valign="top" align="center" rowspan="1" colspan="1">1.842 (1.232–2.754)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">0.003</td>
            </tr>
            <tr>
              <td valign="top" align="left" rowspan="1" colspan="1">FABP5 expression</td>
              <td valign="top" align="center" rowspan="1" colspan="1">2.984 (2.116–4.208)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td>
              <td valign="top" align="center" rowspan="1" colspan="1">2.187 (1.488–3.214)</td>
              <td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>Furthermore, we also found that the prognostic abilities of <italic>CD302</italic> and <italic>FABP5</italic> were independent of the critical clinical features of LGG patients, including histologic grade, therapy and primary therapy outcome (<xref ref-type="fig" rid="F8">Figures 8</xref>, <xref ref-type="fig" rid="F9">9</xref>, <xref ref-type="supplementary-material" rid="SM6">Figures S6</xref>, <xref ref-type="supplementary-material" rid="SM7">S7</xref>). In detail, patients with <italic>CD302</italic>/<italic>FABP5</italic> overexpression exhibited worse survival in both histologic grade 2 and 3 (<xref ref-type="fig" rid="F8">Figure 8</xref>), both stable and progressive disease (<xref ref-type="fig" rid="F9">Figure 9</xref>), and both radiotherapy and TMZ (temozolomide) therapy (<xref ref-type="supplementary-material" rid="SM6">Figures S6</xref>, <xref ref-type="supplementary-material" rid="SM7">S7</xref>), while no significant prognostic significance of <italic>CD302/FABP5</italic> observed in patients with complete and partial response.</p>
      <fig id="F8" position="float">
        <label>Figure 8</label>
        <caption>
          <p>The prognostic abilities of <italic>CD302</italic> and <italic>FABP5</italic> in terms of histologic grade. Kaplan-Meier plots for <italic>CD302</italic> in histologic grade 2 <bold>(A)</bold> and 3 <bold>(B)</bold>, and for <italic>FABP5</italic> in histologic grade 2 <bold>(C)</bold> and 3 <bold>(D)</bold>, respectively. <italic>p</italic>-value, confidence interval (95%CI) and number at risk are as shown. The y-axis represents survival rate and the x-axis represents survival time (months).</p>
        </caption>
        <graphic xlink:href="fonc-10-01097-g0008"/>
      </fig>
      <fig id="F9" position="float">
        <label>Figure 9</label>
        <caption>
          <p>The prognostic abilities of <italic>CD302</italic> and <italic>FABP5</italic> in terms of primary therapy outcome. Kaplan-Meier plots for <italic>CD302</italic> in stable <bold>(A)</bold> and progressive <bold>(B)</bold> disease, and for <italic>FABP5</italic> in stable <bold>(C)</bold> and progressive <bold>(D)</bold> disease, respectively. <italic>p</italic>-value, confidence interval (95%CI) and number at risk are as shown. The y-axis represents survival rate and the x-axis represents survival time (months).</p>
        </caption>
        <graphic xlink:href="fonc-10-01097-g0009"/>
      </fig>
    </sec>
  </sec>
  <sec sec-type="discussion" id="s4">
    <title>Discussion</title>
    <p>Gliomas are graded as I to IV according to the histology and clinical criteria. Grade II and III glioma are designated as low-grade glioma (LGG) (<xref rid="B1" ref-type="bibr">1</xref>–<xref rid="B4" ref-type="bibr">4</xref>). Although LGG accounts for a minority of gliomas, it is the major cause of mortality for young adults (<xref rid="B14" ref-type="bibr">14</xref>). Although the survival outcomes for patients diagnosed with LGG are better than those for high-grade gliomas, LGG almost universally advances to high-grade glioma (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B8" ref-type="bibr">8</xref>). Surgical resection is the major treatment for LGG. However, even under gross total resection (GTR), the survival rates of LGG patients are still low, having the risk of tumor progression (<xref rid="B9" ref-type="bibr">9</xref>). Some low-risk patients exhibit tumor progression-free without intervention, while others with high-risk suffer from the progressive disease, for which intervention treatment may be given after being diagnosed (<xref rid="B6" ref-type="bibr">6</xref>). As the patients suffering from LGG have distinct clinical performances, it is necessary to classify patients into subgroups with different risks to guide following treatments.</p>
    <p>In this study, we developed a web server OSlgg, by which users could evaluate the prognostic value of genes of interest even for users with limited bioinformatics skills. To determine the reliability of OSlgg, we have verified the prognostic roles of 86 previously reported LGG prognostic biomarkers including IDH1, BIRC5, CDKN1B, PCNA, and MKI67. Furthermore, we have identified two novel potential prognostic biomarkers for LGG patients, including CD302 and FABP5. As C-type lectin receptor, CD302 has roles in cell immune and migration (<xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B36" ref-type="bibr">36</xref>), and acts as a prognostic biomarker in myeloma (<xref rid="B37" ref-type="bibr">37</xref>), is also a potential therapeutic target for acute myeloid leukemia (<xref rid="B38" ref-type="bibr">38</xref>). In addition, CD302 had been identified as a biomarker to categorize the metastases of neuroendocrine tumors (NET) (<xref rid="B39" ref-type="bibr">39</xref>), and it is reported to be overexpressed in high grade NET (<xref rid="B40" ref-type="bibr">40</xref>). Fatty acid-binding protein 5 (FABP5) is involved in fatty acid transport, and acts as a prognostic biomarker in cervical cancer, triple-negative breast cancer and clear cell renal cell carcinoma (<xref rid="B41" ref-type="bibr">41</xref>–<xref rid="B43" ref-type="bibr">43</xref>). In addition, FABP5 was found to be expressed in 9 of 23 gliomas with moderate to strong cytoplasmic staining in Human Protein Atlas (HPA) database, and was reported to be expressed in grade II (19/30) and III (22/31) astrocytoma (a histologic subtype of glioma) (<xref rid="B44" ref-type="bibr">44</xref>). The prognostic abilities of CD302 and FABP5 have not been reported in LGG yet. In our server, the cox regression analysis reveals that CD302 and FABP5 are significantly correlated with survival outcomes of LGG patients, patients with lower expression of CD302 and FABP5 have improved outcomes compared to patients with higher expression of these genes, and we found that the elevated <italic>CD302</italic>/<italic>FABP5</italic> expression was significantly associated with higher histologic grade and worse therapeutic outcome, in the meanwhile, we found that CD302 and FABP5 were independent prognostic indicators of LGG.</p>
    <p>Additional correlation analysis showed that <italic>CD302</italic> and <italic>FABP5</italic> were significantly correlated with 6 of 86 reported unfavorable prognostic biomarkers including <italic>RAB34, CHI3L1, VIM, YAP1, FTL</italic>, and <italic>MMP14</italic>, which predicted adverse outcome (<xref rid="B45" ref-type="bibr">45</xref>–<xref rid="B50" ref-type="bibr">50</xref>). These six <italic>CD302/FABP5</italic> correlated genes were reported to be involved in tumor cell proliferation, migration, invasion and EMT (<xref rid="B46" ref-type="bibr">46</xref>–<xref rid="B53" ref-type="bibr">53</xref>). GSEA results showed LGG tumors with high expression of <italic>CD302</italic> or <italic>FABP5</italic> enriched JAK/STAT and ECM receptor interaction signaling pathway, which are reported to be involved in tumorigenesis and could promote tumor progression (<xref rid="B54" ref-type="bibr">54</xref>, <xref rid="B55" ref-type="bibr">55</xref>). Moreover, LGG tumors with <italic>CD302</italic> or <italic>FABP5</italic> overexpression highly expressed some oncogenes, including <italic>GPR65, PIK3CG, CHI3L1</italic>, and <italic>RAB36</italic>, which were reported to promote tumor growth and metastasis (<xref rid="B56" ref-type="bibr">56</xref>–<xref rid="B60" ref-type="bibr">60</xref>). Taken together, our results highlight the clinical significance of <italic>CD302</italic> and <italic>FABP5</italic> in LGG, the expression of which may have a close association with tumorigenesis and malignant progression of LGG. Further assays for biological functions of these genes may offer opportunities for targeted therapies in LGG.</p>
    <p>The limitation of OSlgg is that currently only 720 LGG cases are available in our server. Once new datasets with profiling and clinical follow-up data become available, we will update OSlgg to expand the dataset and enhance the performance.</p>
    <p>In summary, we developed a prognosis analysis web server OSlgg, which provides a platform for researchers and clinicians to evaluate the prognostic values of genes of interest, and may offer opportunities to facilitate the development of novel targeted strategies for LGG.</p>
  </sec>
  <sec sec-type="data-availability" id="s5">
    <title>Data Availability Statement</title>
    <p>Publicly available datasets were analyzed in this study. This data can be found here: TCGA database (<ext-link ext-link-type="uri" xlink:href="https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga">https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga</ext-link>) and GEO database (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/gds/?term=">https://www.ncbi.nlm.nih.gov/gds/?term=</ext-link>).</p>
  </sec>
  <sec id="s6">
    <title>Author Contributions</title>
    <p>YA, QW, and XG developed the server, performed the evaluation of novel prognostic biomarkers, and drafted the paper. LZ, FS, GZ, and HD performed the validation of previous reported biomarkers. HL, YL, and YP collected LGG datasets. WZ, SJ, and YW contributed to data analysis and paper revision. All authors approved the final manuscript.</p>
  </sec>
  <sec id="s7">
    <title>Conflict of Interest</title>
    <p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
  </sec>
</body>
<back>
  <fn-group>
    <fn fn-type="financial-disclosure">
      <p><bold>Funding.</bold> This work was supported by National Natural Science Foundation of China (No. 81602362), and Program for Innovative Talents of Science and Technology in Henan Province (No. 18HASTIT048), Program for Science and Technology Development in Henan Province (No. 162102310391; No. 172102210187), Program for Scientific and Technological Research of Henan Education Department (No. 14B520022), Kaifeng Science and Technology Major Project (No. 18ZD008), Supporting grant of Bioinformatics Center of Henan University (No. 2018YLJC01), and Innovation Project for College Students of Henan University (No. 2019101904).</p>
    </fn>
  </fn-group>
  <sec sec-type="supplementary-material" id="s8">
    <title>Supplementary Material</title>
    <p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fonc.2020.01097/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fonc.2020.01097/full#supplementary-material</ext-link></p>
    <supplementary-material content-type="local-data" id="SM1">
      <label>Figure S1</label>
      <caption>
        <p>Verification of previously reported prognostic biomarkers in OSlgg. Kaplan-Meier plots for <bold>(A)</bold>
<italic>CDH2</italic>, <bold>(B)</bold>
<italic>EGFR</italic>, <bold>(C)</bold>
<italic>IDH1</italic>, <bold>(D,J)</bold>
<italic>VEGFA</italic>, <bold>(E)</bold>
<italic>NES</italic>, <bold>(F,K)</bold>
<italic>BIRC5</italic>, <bold>(G)</bold>
<italic>PCNA</italic>, <bold>(H)</bold>
<italic>MKI67</italic> and <bold>(I)</bold>
<italic>CDKN1B</italic> in terms of RFS and PFS. <bold>(A–I)</bold> RFS, Relapse-free survival, in TCGA cohort; <bold>(J,K)</bold> PFS, Progression-free survival, in GSE107850 cohort.</p>
      </caption>
      <media xlink:href="Image_1.TIF">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="SM2">
      <label>Figure S2</label>
      <caption>
        <p>Kaplan-Meier plots for housekeeping genes as negative controls. <bold>(A)</bold>
<italic>TUBB1</italic>, <bold>(B)</bold>
<italic>TUBB3</italic> and <bold>(C)</bold>
<italic>ACTA1</italic>, were presented as negative control genes of <xref ref-type="fig" rid="F5">Figure 5</xref>.</p>
      </caption>
      <media xlink:href="Image_2.TIF">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="SM3">
      <label>Figure S3</label>
      <caption>
        <p>Prognostic analysis of reported oncogenes up-regulated in <italic>CD302</italic>/<italic>FABP5</italic> overexpression cohort. Kaplan-Meier plots for <bold>(A)</bold>
<italic>GPR65</italic>, <bold>(B)</bold>
<italic>PIK3CG</italic>, <bold>(C)</bold>
<italic>CHI3L</italic>1 and <bold>(D)</bold>
<italic>RAB36</italic>. <italic>p</italic>-value, confidence interval (95%CI) and number at risk are as shown. The y-axis represents survival rate and the x-axis represents survival time (months).</p>
      </caption>
      <media xlink:href="Image_3.TIF">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="SM4">
      <label>Figure S4</label>
      <caption>
        <p>Analysis of the relationship between mRNA expression and copy number variation of <italic>CD302</italic>
<bold>(A)</bold> and <italic>FABP5</italic>
<bold>(B)</bold> in 508 LGG patients.</p>
      </caption>
      <media xlink:href="Image_4.TIF">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="SM5">
      <label>Figure S5</label>
      <caption>
        <p>Comparison of <italic>CD302/FABP5</italic> expression differences in distinct clinical features. <bold>(A,B)</bold> histologic grade, <bold>(C,D)</bold> primary therapy outcome. TPM, Transcripts Per Million.</p>
      </caption>
      <media xlink:href="Image_5.TIF">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="SM6">
      <label>Figure S6</label>
      <caption>
        <p>The prognostic abilities of <italic>CD302</italic> and <italic>FABP5</italic> in terms of treatment in TCGA cohort. <bold>(A)</bold> Kaplan-Meier plots for radiotherapy treatment in all tumors. <bold>(B,C)</bold> Kaplan-Meier plots for <italic>CD302</italic> high vs. low expression in tumors with and without radiotherapy, respectively. <bold>(D,E)</bold> Kaplan-Meier plots for <italic>FABP5</italic> high vs. low expression in tumors with and without radiotherapy, respectively. <italic>p</italic>-value is as shown. The y-axis represents survival rate and the x-axis represents survival time (months).</p>
      </caption>
      <media xlink:href="Image_6.TIF">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="SM7">
      <label>Figure S7</label>
      <caption>
        <p>The prognostic abilities of <italic>CD302</italic> and <italic>FABP5</italic> in terms of treatment in GSE107850 cohort. <bold>(A,B)</bold> Kaplan-Meier plots for <italic>CD302</italic> in radiotherapy and TMZ (temozolomide) therapy, respectively. <bold>(C,D)</bold> Kaplan-Meier plots for <italic>FABP5</italic> in radiotherapy and TMZ (temozolomide) therapy, respectively. <italic>p</italic>-value, confidence interval (95%CI) and number at risk are as shown. The y-axis represents survival rate and the x-axis represents survival time (months).</p>
      </caption>
      <media xlink:href="Image_7.TIF">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="SM8">
      <label>Table S1</label>
      <caption>
        <p>Clinicopathologic Characteristics of LGG patients.</p>
      </caption>
      <media xlink:href="Table_1.XLSX">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="SM9">
      <label>Table S2</label>
      <caption>
        <p>Verification of previous published predictors for LGG survival in OSlgg.</p>
      </caption>
      <media xlink:href="Table_2.XLSX">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
  <ref-list>
    <title>References</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>YA</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Song</surname><given-names>K</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Sathe</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>SHOX2 is a potent independent biomarker to predict survival of WHO Grade II-III Diffuse Gliomas</article-title>. <source>EBioMedicine.</source> (<year>2016</year>) <volume>13</volume>:<fpage>80</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.ebiom.2016.10.040</pub-id><?supplied-pmid 27840009?><pub-id pub-id-type="pmid">27840009</pub-id></mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>JH</given-names></name><name><surname>McNulty</surname><given-names>SN</given-names></name><name><surname>Cimino</surname><given-names>PJ</given-names></name><name><surname>Cottrell</surname><given-names>CE</given-names></name><name><surname>Heusel</surname><given-names>JW</given-names></name><name><surname>Vigh-Conrad</surname><given-names>KA</given-names></name><etal/></person-group>. <article-title>Targeted next-generation sequencing in molecular subtyping of lower-grade diffuse gliomas: application of the World Health Organization's 2016 revised criteria for central nervous system tumors</article-title>. <source>J Mol Diagn.</source> (<year>2017</year>) <volume>19</volume>:<fpage>328</fpage>–<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmoldx.2016.10.010</pub-id><?supplied-pmid 28042970?><pub-id pub-id-type="pmid">28042970</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louis</surname><given-names>DN</given-names></name><name><surname>Perry</surname><given-names>A</given-names></name><name><surname>Reifenberger</surname><given-names>G</given-names></name><name><surname>von Deimling</surname><given-names>A</given-names></name><name><surname>Figarella-Branger</surname><given-names>D</given-names></name><name><surname>Cavenee</surname><given-names>WK</given-names></name><etal/></person-group>. <article-title>The 2016 World Health Organization Classification of tumors of the central nervous system: a summary</article-title>. <source>Acta Neuropathol.</source> (<year>2016</year>) <volume>131</volume>:<fpage>803</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1007/s00401-016-1545-1</pub-id><?supplied-pmid 27157931?><pub-id pub-id-type="pmid">27157931</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louis</surname><given-names>DN</given-names></name><name><surname>Ohgaki</surname><given-names>H</given-names></name><name><surname>Wiestler</surname><given-names>OD</given-names></name><name><surname>Cavenee</surname><given-names>WK</given-names></name><name><surname>Burger</surname><given-names>PC</given-names></name><name><surname>Jouvet</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>The 2007 WHO classification of tumours of the central nervous system</article-title>. <source>Acta Neuropathol.</source> (<year>2007</year>) <volume>114</volume>:<fpage>97</fpage>–<lpage>109</lpage>. <pub-id pub-id-type="doi">10.1007/s00401-007-0243-4</pub-id><?supplied-pmid 17618441?><pub-id pub-id-type="pmid">17618441</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Claus</surname><given-names>EB</given-names></name><name><surname>Walsh</surname><given-names>KM</given-names></name><name><surname>Wiencke</surname><given-names>JK</given-names></name><name><surname>Molinaro</surname><given-names>AM</given-names></name><name><surname>Wiemels</surname><given-names>JL</given-names></name><name><surname>Schildkraut</surname><given-names>JM</given-names></name><etal/></person-group>. <article-title>Survival and low-grade glioma: the emergence of genetic information</article-title>. <source>Neurosurg Focus.</source> (<year>2015</year>) <volume>38</volume>:<fpage>E6</fpage>. <pub-id pub-id-type="doi">10.3171/2014.10.FOCUS12367</pub-id><?supplied-pmid 25552286?><pub-id pub-id-type="pmid">25552286</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiff</surname><given-names>D</given-names></name><name><surname>Brown</surname><given-names>PD</given-names></name><name><surname>Giannini</surname><given-names>C</given-names></name></person-group>. <article-title>Outcome in adult low-grade glioma: the impact of prognostic factors and treatment</article-title>. <source>Neurology.</source> (<year>2007</year>) <volume>69</volume>:<fpage>1366</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1212/01.wnl.0000277271.47601.a1</pub-id><?supplied-pmid 17893297?><pub-id pub-id-type="pmid">17893297</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahm</surname><given-names>F</given-names></name><name><surname>Reuss</surname><given-names>D</given-names></name><name><surname>Koelsche</surname><given-names>C</given-names></name><name><surname>Capper</surname><given-names>D</given-names></name><name><surname>Schittenhelm</surname><given-names>J</given-names></name><name><surname>Heim</surname><given-names>S</given-names></name><etal/></person-group><article-title>Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma</article-title>. <source>Acta Neuropathol.</source> (<year>2014</year>) <volume>128</volume>:<fpage>551</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1007/s00401-014-1326-7</pub-id><pub-id pub-id-type="pmid">25143301</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bready</surname><given-names>D</given-names></name><name><surname>Placantonakis</surname><given-names>DG</given-names></name></person-group>. <article-title>Molecular Pathogenesis of Low-Grade Glioma</article-title>. <source>Neurosurg Clin N Am.</source> (<year>2019</year>) <volume>30</volume>:<fpage>17</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1016/j.nec.2018.08.011</pub-id><?supplied-pmid 30470401?><pub-id pub-id-type="pmid">30470401</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedersen</surname><given-names>CL</given-names></name><name><surname>Romner</surname><given-names>B</given-names></name></person-group>. <article-title>Current treatment of low grade astrocytoma: a review</article-title>. <source>Clin Neurol Neurosurg.</source> (<year>2013</year>) <volume>115</volume>:<fpage>1</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.clineuro.2012.07.002</pub-id><?supplied-pmid 22819718?><pub-id pub-id-type="pmid">22819718</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olar</surname><given-names>A</given-names></name><name><surname>Sulman</surname><given-names>EP</given-names></name></person-group>. <article-title>Molecular markers in low-grade glioma-toward tumor reclassification</article-title>. <source>Semin Radiat Oncol.</source> (<year>2015</year>) <volume>25</volume>:<fpage>155</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/j.semradonc.2015.02.006</pub-id><?supplied-pmid 26050585?><pub-id pub-id-type="pmid">26050585</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>AL</given-names></name><name><surname>Colman</surname><given-names>H</given-names></name></person-group>. <article-title>Glioma biology and molecular markers</article-title>. <source>Cancer Treat Res.</source> (<year>2015</year>) <volume>163</volume>:<fpage>15</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-319-12048-5_2</pub-id><?supplied-pmid 25468223?><pub-id pub-id-type="pmid">25468223</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiler</surname><given-names>M</given-names></name><name><surname>Wick</surname><given-names>W</given-names></name></person-group>. <article-title>Molecular predictors of outcome in low-grade glioma</article-title>. <source>Curr Opin Neurol.</source> (<year>2012</year>) <volume>25</volume>:<fpage>767</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1097/WCO.0b013e32835a0217</pub-id><?supplied-pmid 23160425?><pub-id pub-id-type="pmid">23160425</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stupp</surname><given-names>R</given-names></name><name><surname>Janzer</surname><given-names>RC</given-names></name><name><surname>Hegi</surname><given-names>ME</given-names></name><name><surname>Villemure</surname><given-names>JG</given-names></name><name><surname>Mirimanoff</surname><given-names>RO</given-names></name></person-group>. <article-title>Prognostic factors for low-grade gliomas</article-title>. <source>Semin Oncol.</source> (<year>2003</year>) <volume>30</volume>(<issue>6 Suppl 19</issue>):23–8. <pub-id pub-id-type="doi">10.1053/j.seminoncol.2003.11.029</pub-id><?supplied-pmid 14765381?><pub-id pub-id-type="pmid">14765381</pub-id></mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Picca</surname><given-names>A</given-names></name><name><surname>Berzero</surname><given-names>G</given-names></name><name><surname>Sanson</surname><given-names>M</given-names></name></person-group>. <article-title>Current therapeutic approaches to diffuse grade II and III gliomas</article-title>. <source>Ther Adv Neurol Disord.</source> (<year>2018</year>) <volume>11</volume>:<fpage>1756285617752039</fpage>. <pub-id pub-id-type="doi">10.1177/1756285617752039</pub-id><?supplied-pmid 29403544?><pub-id pub-id-type="pmid">29403544</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Yuan</surname><given-names>Q</given-names></name><name><surname>Dang</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>OSblca: a web server for investigating prognostic biomarkers of bladder cancer patients</article-title>. <source>Front Oncol.</source> (<year>2019</year>) <volume>9</volume>:<fpage>466</fpage>. <pub-id pub-id-type="doi">10.3389/fonc.2019.00466</pub-id><?supplied-pmid 31275847?><pub-id pub-id-type="pmid">31275847</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Xie</surname><given-names>L</given-names></name><name><surname>Dang</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Xie</surname><given-names>T</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>OSlms: a web server to evaluate the prognostic value of genes in leiomyosarcoma</article-title>. <source>Front Oncol.</source> (<year>2019</year>) <volume>9</volume>:<fpage>190</fpage>. <pub-id pub-id-type="doi">10.3389/fonc.2019.00190</pub-id><?supplied-pmid 30984618?><pub-id pub-id-type="pmid">30984618</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Dang</surname><given-names>Y</given-names></name><name><surname>Ge</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>OSkirc: a web tool for identifying prognostic biomarkers in kidney renal clear cell carcinoma</article-title>. <source>Future Oncol.</source> (<year>2019</year>) <volume>15</volume>:<fpage>3103</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.2217/fon-2019-0296</pub-id><?supplied-pmid 31368353?><pub-id pub-id-type="pmid">31368353</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Lv</surname><given-names>J</given-names></name><name><surname>Xin</surname><given-names>J</given-names></name><name><surname>Xie</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Interactive online consensus survival tool for esophageal squamous cell carcinoma prognosis analysis</article-title>. <source>Oncol Lett.</source> (<year>2019</year>) <volume>18</volume>:<fpage>1199</fpage>–<lpage>206</lpage>. <pub-id pub-id-type="doi">10.3892/ol.2019.10440</pub-id><?supplied-pmid 31423180?><pub-id pub-id-type="pmid">31423180</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noh</surname><given-names>MG</given-names></name><name><surname>Oh</surname><given-names>SJ</given-names></name><name><surname>Ahn</surname><given-names>EJ</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Jung</surname><given-names>TY</given-names></name><name><surname>Jung</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Prognostic significance of E-cadherin and N-cadherin expression in Gliomas</article-title>. <source>BMC Cancer.</source> (<year>2017</year>) <volume>17</volume>:<fpage>583</fpage>. <pub-id pub-id-type="doi">10.1186/s12885-017-3591-z</pub-id><?supplied-pmid 28851312?><pub-id pub-id-type="pmid">28851312</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varela</surname><given-names>M</given-names></name><name><surname>Ranuncolo</surname><given-names>SM</given-names></name><name><surname>Morand</surname><given-names>A</given-names></name><name><surname>Lastiri</surname><given-names>J</given-names></name><name><surname>De Kier Joffe</surname><given-names>EB</given-names></name><name><surname>Puricelli</surname><given-names>LI</given-names></name><etal/></person-group>. <article-title>EGF-R and PDGF-R, but not bcl-2, overexpression predict overall survival in patients with low-grade astrocytomas</article-title>. <source>J Surg Oncol.</source> (<year>2004</year>) <volume>86</volume>:<fpage>34</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1002/jso.20036</pub-id><?supplied-pmid 15048678?><pub-id pub-id-type="pmid">15048678</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nabika</surname><given-names>S</given-names></name><name><surname>Kiya</surname><given-names>K</given-names></name><name><surname>Satoh</surname><given-names>H</given-names></name><name><surname>Mizoue</surname><given-names>T</given-names></name><name><surname>Kondo</surname><given-names>H</given-names></name><name><surname>Katagiri</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Prognostic significance of expression patterns of EGFR family, p21 and p27 in high-grade astrocytoma</article-title>. <source>Hiroshima J Med Sci.</source> (<year>2010</year>) <volume>59</volume>:<fpage>65</fpage>–<lpage>70</lpage>.<?supplied-pmid 21361082?><pub-id pub-id-type="pmid">21361082</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>MY</given-names></name><name><surname>Wang</surname><given-names>YY</given-names></name><name><surname>Cai</surname><given-names>JQ</given-names></name><name><surname>Zhang</surname><given-names>CB</given-names></name><name><surname>Wang</surname><given-names>KY</given-names></name><name><surname>Cheng</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Isocitrate dehydrogenase 1 gene mutation is associated with prognosis in clinical low-grade gliomas</article-title>. <source>PLoS ONE.</source> (<year>2015</year>) <volume>10</volume>:<fpage>e0130872</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0130872</pub-id><?supplied-pmid 26115094?><pub-id pub-id-type="pmid">26115094</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdulrauf</surname><given-names>SI</given-names></name><name><surname>Edvardsen</surname><given-names>K</given-names></name><name><surname>Ho</surname><given-names>KL</given-names></name><name><surname>Yang</surname><given-names>XY</given-names></name><name><surname>Rock</surname><given-names>JP</given-names></name><name><surname>Rosenblum</surname><given-names>ML</given-names></name></person-group>. <article-title>Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma</article-title>. <source>J Neurosurg.</source> (<year>1998</year>) <volume>88</volume>:<fpage>513</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.3171/jns.1998.88.3.0513</pub-id><?supplied-pmid 9488306?><pub-id pub-id-type="pmid">9488306</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karayan-Tapon</surname><given-names>L</given-names></name><name><surname>Wager</surname><given-names>M</given-names></name><name><surname>Guilhot</surname><given-names>J</given-names></name><name><surname>Levillain</surname><given-names>P</given-names></name><name><surname>Marquant</surname><given-names>C</given-names></name><name><surname>Clarhaut</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Semaphorin, neuropilin and VEGF expression in glial tumours: SEMA3G, a prognostic marker?</article-title><source>Br J Cancer.</source> (<year>2008</year>) <volume>99</volume>:<fpage>1153</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjc.6604641</pub-id><?supplied-pmid 18781179?><pub-id pub-id-type="pmid">18781179</pub-id></mixed-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatanpaa</surname><given-names>KJ</given-names></name><name><surname>Hu</surname><given-names>T</given-names></name><name><surname>Vemireddy</surname><given-names>V</given-names></name><name><surname>Foong</surname><given-names>C</given-names></name><name><surname>Raisanen</surname><given-names>JM</given-names></name><name><surname>Oliver</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>High expression of the stem cell marker nestin is an adverse prognostic factor in WHO grade II-III astrocytomas and oligoastrocytomas</article-title>. <source>J Neurooncol.</source> (<year>2014</year>) <volume>117</volume>:<fpage>183</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1007/s11060-014-1376-7</pub-id><?supplied-pmid 24519516?><pub-id pub-id-type="pmid">24519516</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Song</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients</article-title>. <source>J Exp Clin Cancer Res.</source> (<year>2008</year>) <volume>27</volume>:<fpage>85</fpage>. <pub-id pub-id-type="doi">10.1186/1756-9966-27-85</pub-id><?supplied-pmid 19108713?><pub-id pub-id-type="pmid">19108713</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strojnik</surname><given-names>T</given-names></name><name><surname>Rosland</surname><given-names>GV</given-names></name><name><surname>Sakariassen</surname><given-names>PO</given-names></name><name><surname>Kavalar</surname><given-names>R</given-names></name><name><surname>Lah</surname><given-names>T</given-names></name></person-group>. <article-title>Neural stem cell markers, nestin and musashi proteins, in the progression of human glioma: correlation of nestin with prognosis of patient survival</article-title>. <source>Surg Neurol.</source> (<year>2007</year>) <volume>68</volume>:<fpage>133</fpage>–<lpage>43</lpage>; discussion 43–4. <pub-id pub-id-type="doi">10.1016/j.surneu.2006.10.050</pub-id><?supplied-pmid 17537489?><pub-id pub-id-type="pmid">17537489</pub-id></mixed-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uematsu</surname><given-names>M</given-names></name><name><surname>Ohsawa</surname><given-names>I</given-names></name><name><surname>Aokage</surname><given-names>T</given-names></name><name><surname>Nishimaki</surname><given-names>K</given-names></name><name><surname>Matsumoto</surname><given-names>K</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Prognostic significance of the immunohistochemical index of survivin in glioma: a comparative study with the MIB-1 index</article-title>. <source>J Neurooncol.</source> (<year>2005</year>) <volume>72</volume>:<fpage>231</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1007/s11060-004-2353-3</pub-id><?supplied-pmid 15937645?><pub-id pub-id-type="pmid">15937645</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vigliani</surname><given-names>MC</given-names></name><name><surname>Chio</surname><given-names>A</given-names></name><name><surname>Pezzulo</surname><given-names>T</given-names></name><name><surname>Soffietti</surname><given-names>R</given-names></name><name><surname>Giordana</surname><given-names>MT</given-names></name><name><surname>Schiffer</surname><given-names>D</given-names></name></person-group>. <article-title>Proliferating cell nuclear antigen (PCNA) in low-grade astrocytomas: its prognostic significance</article-title>. <source>Tumori.</source> (<year>1994</year>) <volume>80</volume>:<fpage>295</fpage>–<lpage>300</lpage>. <pub-id pub-id-type="doi">10.1177/030089169408000411</pub-id><?supplied-pmid 7974802?><pub-id pub-id-type="pmid">7974802</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>BJ</given-names></name><name><surname>Naumova</surname><given-names>E</given-names></name><name><surname>Leighton</surname><given-names>CC</given-names></name><name><surname>Naumov</surname><given-names>GN</given-names></name><name><surname>Kerklviet</surname><given-names>N</given-names></name><name><surname>Fortin</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Ki-67: a prognostic factor for low-grade glioma?</article-title><source>Int J Radiat Oncol Biol Phys.</source> (<year>2002</year>) <volume>52</volume>:<fpage>996</fpage>–<lpage>1001</lpage>. <pub-id pub-id-type="doi">10.1016/S0360-3016(01)02720-1</pub-id><?supplied-pmid 11958894?><pub-id pub-id-type="pmid">11958894</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>A</given-names></name><name><surname>Hu</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Cui</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma</article-title>. <source>Oncotarget.</source> (<year>2015</year>) <volume>6</volume>:<fpage>30232</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.4920</pub-id><?supplied-pmid 26338964?><pub-id pub-id-type="pmid">26338964</pub-id></mixed-citation>
    </ref>
    <ref id="B32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>S</given-names></name><name><surname>Rashed</surname><given-names>H</given-names></name><name><surname>Hegazy</surname><given-names>A</given-names></name><name><surname>Mohamed</surname><given-names>AM</given-names></name><name><surname>Elmesallamy</surname><given-names>W</given-names></name></person-group>. <article-title>Prognostic value of ALDH1, EZH2 and Ki-67 in astrocytic gliomas</article-title>. <source>Turk Patoloji Derg.</source> (<year>2016</year>) <volume>32</volume>:<fpage>70</fpage>–<lpage>81</lpage>. <pub-id pub-id-type="doi">10.5146/tjpath.2015.01344</pub-id><?supplied-pmid 27136105?><pub-id pub-id-type="pmid">27136105</pub-id></mixed-citation>
    </ref>
    <ref id="B33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirla</surname><given-names>RM</given-names></name><name><surname>Haapasalo</surname><given-names>HK</given-names></name><name><surname>Kalimo</surname><given-names>H</given-names></name><name><surname>Salminen</surname><given-names>EK</given-names></name></person-group>. <article-title>Low expression of p27 indicates a poor prognosis in patients with high-grade astrocytomas</article-title>. <source>Cancer.</source> (<year>2003</year>) <volume>97</volume>:<fpage>644</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1002/cncr.11079</pub-id><?supplied-pmid 12548606?><pub-id pub-id-type="pmid">12548606</pub-id></mixed-citation>
    </ref>
    <ref id="B34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizumatsu</surname><given-names>S</given-names></name><name><surname>Tamiya</surname><given-names>T</given-names></name><name><surname>Ono</surname><given-names>Y</given-names></name><name><surname>Abe</surname><given-names>T</given-names></name><name><surname>Matsumoto</surname><given-names>K</given-names></name><name><surname>Furuta</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Expression of cell cycle regulator p27Kip1 is correlated with survival of patients with astrocytoma</article-title>. <source>Clin Cancer Res.</source> (<year>1999</year>) <volume>5</volume>:<fpage>551</fpage>–<lpage>7</lpage>.<?supplied-pmid 10100706?><pub-id pub-id-type="pmid">10100706</pub-id></mixed-citation>
    </ref>
    <ref id="B35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lo</surname><given-names>TH</given-names></name><name><surname>Silveira</surname><given-names>PA</given-names></name><name><surname>Fromm</surname><given-names>PD</given-names></name><name><surname>Verma</surname><given-names>ND</given-names></name><name><surname>Vu</surname><given-names>PA</given-names></name><name><surname>Kupresanin</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Characterization of the expression and function of the C-Type lectin receptor cd302 in mice and humans reveals a role in dendritic cell migration</article-title>. <source>J Immunol.</source> (<year>2016</year>) <volume>197</volume>:<fpage>885</fpage>–<lpage>98</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1600259</pub-id><?supplied-pmid 27316686?><pub-id pub-id-type="pmid">27316686</pub-id></mixed-citation>
    </ref>
    <ref id="B36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>M</given-names></name><name><surname>Khan</surname><given-names>S</given-names></name><name><surname>d'Aniello</surname><given-names>E</given-names></name><name><surname>McDonald</surname><given-names>KJ</given-names></name><name><surname>Hart</surname><given-names>DN</given-names></name></person-group>. <article-title>The novel endocytic and phagocytic C-Type lectin receptor DCL-1/CD302 on macrophages is colocalized with F-actin, suggesting a role in cell adhesion and migration</article-title>. <source>J Immunol.</source> (<year>2007</year>) <volume>179</volume>:<fpage>6052</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.179.9.6052</pub-id><?supplied-pmid 17947679?><pub-id pub-id-type="pmid">17947679</pub-id></mixed-citation>
    </ref>
    <ref id="B37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alaterre</surname><given-names>E</given-names></name><name><surname>Raimbault</surname><given-names>S</given-names></name><name><surname>Goldschmidt</surname><given-names>H</given-names></name><name><surname>Bouhya</surname><given-names>S</given-names></name><name><surname>Requirand</surname><given-names>G</given-names></name><name><surname>Robert</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma</article-title>. <source>Oncotarget.</source> (<year>2017</year>) <volume>8</volume>:<fpage>98931</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.22131</pub-id><?supplied-pmid 29228738?><pub-id pub-id-type="pmid">29228738</pub-id></mixed-citation>
    </ref>
    <ref id="B38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lo</surname><given-names>TH</given-names></name><name><surname>Abadir</surname><given-names>E</given-names></name><name><surname>Gasiorowski</surname><given-names>RE</given-names></name><name><surname>Kabani</surname><given-names>K</given-names></name><name><surname>Ramesh</surname><given-names>M</given-names></name><name><surname>Orellana</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Examination of CD302 as a potential therapeutic target for acute myeloid leukemia</article-title>. <source>PLoS ONE.</source> (<year>2019</year>) <volume>14</volume>:<fpage>e0216368</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0216368</pub-id><?supplied-pmid 31075107?><pub-id pub-id-type="pmid">31075107</pub-id></mixed-citation>
    </ref>
    <ref id="B39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Posorski</surname><given-names>N</given-names></name><name><surname>Kaemmerer</surname><given-names>D</given-names></name><name><surname>Ernst</surname><given-names>G</given-names></name><name><surname>Grabowski</surname><given-names>P</given-names></name><name><surname>Hoersch</surname><given-names>D</given-names></name><name><surname>Hommann</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Localization of sporadic neuroendocrine tumors by gene expression analysis of their metastases</article-title>. <source>Clin Exp Metastasis.</source> (<year>2011</year>) <volume>28</volume>:<fpage>637</fpage>–<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1007/s10585-011-9397-5</pub-id><?supplied-pmid 21681495?><pub-id pub-id-type="pmid">21681495</pub-id></mixed-citation>
    </ref>
    <ref id="B40">
      <label>40.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaemmerer</surname><given-names>D</given-names></name><name><surname>Posorski</surname><given-names>N</given-names></name><name><surname>von Eggeling</surname><given-names>F</given-names></name><name><surname>Ernst</surname><given-names>G</given-names></name><name><surname>Horsch</surname><given-names>D</given-names></name><name><surname>Baum</surname><given-names>RP</given-names></name><etal/></person-group>. <article-title>The search for the primary tumor in metastasized gastroenteropancreatic neuroendocrine neoplasm</article-title>. <source>Clin Exp Metastasis.</source> (<year>2014</year>) <volume>31</volume>:<fpage>817</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1007/s10585-014-9672-3</pub-id><?supplied-pmid 25098566?><pub-id pub-id-type="pmid">25098566</pub-id></mixed-citation>
    </ref>
    <ref id="B41">
      <label>41.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>RZ</given-names></name><name><surname>Graham</surname><given-names>K</given-names></name><name><surname>Glubrecht</surname><given-names>DD</given-names></name><name><surname>Germain</surname><given-names>DR</given-names></name><name><surname>Mackey</surname><given-names>JR</given-names></name><name><surname>Godbout</surname><given-names>R</given-names></name></person-group>. <article-title>Association of FABP5 expression with poor survival in triple-negative breast cancer: implication for retinoic acid therapy</article-title>. <source>Am J Pathol.</source> (<year>2011</year>) <volume>178</volume>:<fpage>997</fpage>–<lpage>1008</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajpath.2010.11.075</pub-id><?supplied-pmid 21356353?><pub-id pub-id-type="pmid">21356353</pub-id></mixed-citation>
    </ref>
    <ref id="B42">
      <label>42.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Han</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>FABP5 is correlated with poor prognosis and promotes tumour cell growth and metastasis in clear cell renal cell carcinoma</article-title>. <source>Eur J Pharmacol.</source> (<year>2019</year>) <volume>862</volume>:<fpage>172637</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2019.172637</pub-id><?supplied-pmid 31491402?><pub-id pub-id-type="pmid">31491402</pub-id></mixed-citation>
    </ref>
    <ref id="B43">
      <label>43.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Chu</surname><given-names>HJ</given-names></name><name><surname>Liang</surname><given-names>YC</given-names></name><name><surname>Huang</surname><given-names>JM</given-names></name><name><surname>Shang</surname><given-names>CL</given-names></name><name><surname>Tan</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>FABP5 correlates with poor prognosis and promotes tumor cell growth and metastasis in cervical cancer</article-title>. <source>Tumour Biol.</source> (<year>2016</year>) <volume>37</volume>:<fpage>14873</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1007/s13277-016-5350-1</pub-id><?supplied-pmid 27644245?><pub-id pub-id-type="pmid">27644245</pub-id></mixed-citation>
    </ref>
    <ref id="B44">
      <label>44.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>SL</given-names></name><name><surname>Wu</surname><given-names>ML</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>JH</given-names></name><name><surname>Chen</surname><given-names>NN</given-names></name><name><surname>Chen</surname><given-names>XY</given-names></name><etal/></person-group>. <article-title>CRABP-II- and FABP5-independent responsiveness of human glioblastoma cells to all-trans retinoic acid</article-title>. <source>Oncotarget.</source> (<year>2015</year>) <volume>6</volume>:<fpage>5889</fpage>–<lpage>902</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.3334</pub-id><?supplied-pmid 25797252?><pub-id pub-id-type="pmid">25797252</pub-id></mixed-citation>
    </ref>
    <ref id="B45">
      <label>45.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>HJ</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>YL</given-names></name><name><surname>Jiang</surname><given-names>CL</given-names></name></person-group>. <article-title>RAB34 was a progression- and prognosis-associated biomarker in gliomas</article-title>. <source>Tumour Biol.</source> (<year>2015</year>) <volume>36</volume>:<fpage>1573</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1007/s13277-014-2732-0</pub-id><?supplied-pmid 25501506?><pub-id pub-id-type="pmid">25501506</pub-id></mixed-citation>
    </ref>
    <ref id="B46">
      <label>46.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steponaitis</surname><given-names>G</given-names></name><name><surname>Skiriute</surname><given-names>D</given-names></name><name><surname>Kazlauskas</surname><given-names>A</given-names></name><name><surname>Golubickaite</surname><given-names>I</given-names></name><name><surname>Stakaitis</surname><given-names>R</given-names></name><name><surname>Tamasauskas</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>High CHI3L1 expression is associated with glioma patient survival</article-title>. <source>Diagn Pathol.</source> (<year>2016</year>) <volume>11</volume>:<fpage>42</fpage>. <pub-id pub-id-type="doi">10.1186/s13000-016-0492-4</pub-id><?supplied-pmid 27121858?><pub-id pub-id-type="pmid">27121858</pub-id></mixed-citation>
    </ref>
    <ref id="B47">
      <label>47.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Ming</surname><given-names>J</given-names></name><name><surname>Meng</surname><given-names>X</given-names></name><name><surname>Han</surname><given-names>B</given-names></name><name><surname>Sun</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Analysis of expression and prognostic significance of vimentin and the response to temozolomide in glioma patients</article-title>. <source>Tumour Biol.</source> (<year>2016</year>) <volume>37</volume>:<fpage>15333</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1007/s13277-016-5462-7</pub-id><?supplied-pmid 27704357?><pub-id pub-id-type="pmid">27704357</pub-id></mixed-citation>
    </ref>
    <ref id="B48">
      <label>48.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guichet</surname><given-names>PO</given-names></name><name><surname>Masliantsev</surname><given-names>K</given-names></name><name><surname>Tachon</surname><given-names>G</given-names></name><name><surname>Petropoulos</surname><given-names>C</given-names></name><name><surname>Godet</surname><given-names>J</given-names></name><name><surname>Larrieu</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Fatal correlation between YAP1 expression and glioma aggressiveness: clinical and molecular evidence</article-title>. <source>J Pathol.</source> (<year>2018</year>) <volume>246</volume>:<fpage>205</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1002/path.5133</pub-id><?supplied-pmid 30009411?><pub-id pub-id-type="pmid">30009411</pub-id></mixed-citation>
    </ref>
    <ref id="B49">
      <label>49.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosager</surname><given-names>AM</given-names></name><name><surname>Sorensen</surname><given-names>MD</given-names></name><name><surname>Dahlrot</surname><given-names>RH</given-names></name><name><surname>Hansen</surname><given-names>S</given-names></name><name><surname>Schonberg</surname><given-names>DL</given-names></name><name><surname>Rich</surname><given-names>JN</given-names></name><etal/></person-group>. <article-title>Transferrin receptor-1 and ferritin heavy and light chains in astrocytic brain tumors: Expression and prognostic value</article-title>. <source>PLoS One.</source> (<year>2017</year>) <volume>12</volume>:<fpage>e0182954</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0182954</pub-id><?supplied-pmid 28837569?><pub-id pub-id-type="pmid">28837569</pub-id></mixed-citation>
    </ref>
    <ref id="B50">
      <label>50.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Tu</surname><given-names>Y</given-names></name><name><surname>Mao</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>S</given-names></name><name><surname>Fu</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Co-expression of MMP-14 and MMP-19 predicts poor survival in human glioma</article-title>. <source>Clin Transl Oncol.</source> (<year>2013</year>) <volume>15</volume>:<fpage>139</fpage>–<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1007/s12094-012-0900-5</pub-id><?supplied-pmid 22855183?><pub-id pub-id-type="pmid">22855183</pub-id></mixed-citation>
    </ref>
    <ref id="B51">
      <label>51.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Tan</surname><given-names>R</given-names></name><name><surname>Qiu</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Rab34 regulates adhesion, migration, and invasion of breast cancer cells</article-title>. <source>Oncogene.</source> (<year>2018</year>) <volume>37</volume>:<fpage>3698</fpage>–<lpage>714</lpage>. <pub-id pub-id-type="doi">10.1038/s41388-018-0202-7</pub-id><?supplied-pmid 29622794?><pub-id pub-id-type="pmid">29622794</pub-id></mixed-citation>
    </ref>
    <ref id="B52">
      <label>52.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Yee</surname><given-names>PP</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Kawasawa</surname><given-names>YI</given-names></name><name><surname>Li</surname><given-names>W</given-names></name></person-group>. <article-title>Differential YAP expression in glioma cells induces cell competition and promotes tumorigenesis</article-title>. <source>J Cell Sci.</source> (<year>2019</year>) <volume>132</volume>:<fpage>5</fpage>. <pub-id pub-id-type="doi">10.1242/jcs.225714</pub-id><?supplied-pmid 30665893?><pub-id pub-id-type="pmid">30665893</pub-id></mixed-citation>
    </ref>
    <ref id="B53">
      <label>53.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Expression of ferritin light chain (FTL) is elevated in glioblastoma, and FTL silencing inhibits glioblastoma cell proliferation via the GADD45/JNK pathway</article-title>. <source>PLoS ONE.</source> (<year>2016</year>) <volume>11</volume>:<fpage>e0149361</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0149361</pub-id><?supplied-pmid 26871431?><pub-id pub-id-type="pmid">26871431</pub-id></mixed-citation>
    </ref>
    <ref id="B54">
      <label>54.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanno</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>H</given-names></name><name><surname>Yokoyama</surname><given-names>TA</given-names></name><name><surname>Yoshizumi</surname><given-names>T</given-names></name><name><surname>Yamada</surname><given-names>S</given-names></name></person-group>. <article-title>The VHL tumor suppressor protein regulates tumorigenicity of U87-derived glioma stem-like cells by inhibiting the JAK/STAT signaling pathway</article-title>. <source>Int J Oncol.</source> (<year>2013</year>) <volume>42</volume>:<fpage>881</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.3892/ijo.2013.1773</pub-id><?supplied-pmid 23338840?><pub-id pub-id-type="pmid">23338840</pub-id></mixed-citation>
    </ref>
    <ref id="B55">
      <label>55.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Yun</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Transcriptome profiling revealed multiple genes and ECM-receptor interaction pathways that may be associated with breast cancer</article-title>. <source>Cell Mol Biol Lett.</source> (<year>2019</year>) <volume>24</volume>:<fpage>38</fpage>. <pub-id pub-id-type="doi">10.1186/s11658-019-0162-0</pub-id><?supplied-pmid 31182966?><pub-id pub-id-type="pmid">31182966</pub-id></mixed-citation>
    </ref>
    <ref id="B56">
      <label>56.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>S</given-names></name><name><surname>Pan</surname><given-names>H</given-names></name><name><surname>Cheng</surname><given-names>Z</given-names></name><name><surname>Rui</surname><given-names>X</given-names></name></person-group>. <article-title>Inhibition of miR-1247 on cell proliferation and invasion in bladder cancer through its downstream target of RAB36</article-title>. <source>J Biosci.</source> (<year>2018</year>) <volume>43</volume>:<fpage>365</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1007/s12038-018-9755-4</pub-id><?supplied-pmid 29872024?><pub-id pub-id-type="pmid">29872024</pub-id></mixed-citation>
    </ref>
    <ref id="B57">
      <label>57.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guerreiro</surname><given-names>AS</given-names></name><name><surname>Fattet</surname><given-names>S</given-names></name><name><surname>Kulesza</surname><given-names>DW</given-names></name><name><surname>Atamer</surname><given-names>A</given-names></name><name><surname>Elsing</surname><given-names>AN</given-names></name><name><surname>Shalaby</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>A sensitized RNA interference screen identifies a novel role for the PI3K p110gamma isoform in medulloblastoma cell proliferation and chemoresistance</article-title>. <source>Mol Cancer Res.</source> (<year>2011</year>) <volume>9</volume>:<fpage>925</fpage>–<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1158/1541-7786.MCR-10-0200</pub-id><?supplied-pmid 21652733?><pub-id pub-id-type="pmid">21652733</pub-id></mixed-citation>
    </ref>
    <ref id="B58">
      <label>58.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>QC</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Jin</surname><given-names>SS</given-names></name><name><surname>Liu</surname><given-names>GF</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>CHI3L1 promotes tumor progression by activating TGF-beta signaling pathway in hepatocellular carcinoma</article-title>. <source>Sci Rep.</source> (<year>2018</year>) <volume>8</volume>:<fpage>15029</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-018-33239-8</pub-id><?supplied-pmid 30301907?><pub-id pub-id-type="pmid">30301907</pub-id></mixed-citation>
    </ref>
    <ref id="B59">
      <label>59.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>HX</given-names></name><name><surname>Chen</surname><given-names>YH</given-names></name><name><surname>Zhou</surname><given-names>JX</given-names></name><name><surname>Hu</surname><given-names>XY</given-names></name><name><surname>Tan</surname><given-names>C</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Overexpression of G-protein-coupled receptors 65 in glioblastoma predicts poor patient prognosis</article-title>. <source>Clin Neurol Neurosurg.</source> (<year>2018</year>) <volume>164</volume>:<fpage>132</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.clineuro.2017.11.017</pub-id><?supplied-pmid 29223793?><pub-id pub-id-type="pmid">29223793</pub-id></mixed-citation>
    </ref>
    <ref id="B60">
      <label>60.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosko</surname><given-names>AE</given-names></name><name><surname>McColl</surname><given-names>KS</given-names></name><name><surname>Zhong</surname><given-names>F</given-names></name><name><surname>Ryder</surname><given-names>CB</given-names></name><name><surname>Chang</surname><given-names>MJ</given-names></name><name><surname>Sattar</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Acidosis sensing receptor GPR65 correlates with anti-apoptotic bcl-2 family member expression in CLL cells: potential implications for the CLL microenvironment</article-title>. <source>J Leuk (Los Angel).</source> (<year>2014</year>) <volume>2</volume>:<fpage>160</fpage>. <pub-id pub-id-type="doi">10.4172/2329-6917.1000160</pub-id>
<?supplied-pmid 25984552?><pub-id pub-id-type="pmid">25984552</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
